文献速递前列腺癌

尿细胞外囊泡GATA2 mRNA可区分前列腺癌疑似患者的活检结果

Urine Extracellular Vesicle GATA2 mRNA Discriminates Biopsy Result in Men with Suspicion of Prostate Cancer.
PubMed 文献 · J Urol · 2020-04-06

本研究分析尿细胞外囊泡GATA2 mRNA单独及联合多基因面板对前列腺癌和高危疾病的预测价值。GATA2 mRNA在前列腺切除后显著下降且与组织水平相关,在训练和验证队列中可区分前列腺癌和高分级疾病。包含GATA2、PCA3和TMPRSS2-ERG的GAPT-E评分较单标志物和PT-E评分提高区分度,并可避免更多不必要活检。

要点

  • 尿细胞外囊泡GATA2 mRNA在前列腺切除后显著下降,证实其前列腺来源。
  • GATA2 mRNA在训练和验证队列中可区分前列腺癌和高分级疾病。
  • GAPT-E评分较单标志物和PT-E评分提高前列腺癌和高危癌区分度。

核心结论

  • 尿细胞外囊泡GATA2 mRNA分析可改善高危前列腺癌检测,并可能减少不必要的活检。

研究设计与样本

  • 匹配分析前列腺切除前后尿液细胞外囊泡(16例)及配对尿液与组织样本(19例)中GATA2 mRNA。
  • 在训练队列(52例)和验证队列(165例)中测试GATA2 mRNA及GAPT-E评分的预测价值。

主要发现

  • 尿细胞外囊泡GATA2 mRNA水平在前列腺切除后显著下降,并与前列腺癌组织GATA2 mRNA水平相关。
  • 训练和验证队列中GATA2区分前列腺癌的AUC分别为0.74和0.66,区分高分级疾病的AUC分别为0.78和0.65。
  • GAPT-E评分在训练和验证队列中区分前列腺癌的AUC分别为0.84和0.72,区分高分级癌的AUC分别为0.85和0.71,优于各单标志物和PT-E。
  • GAPT-E评分用于高分级前列腺癌可避免92.1%的不必要活检,而PT-E评分为61.9%。

临床怎么用

  • 对前列腺癌疑似患者,可考虑检测尿细胞外囊泡GATA2 mRNA及GAPT-E评分以辅助识别高危前列腺癌。
  • GAPT-E评分可能帮助减少不必要的前列腺活检,但需在临床实践中进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Prostate specific antigen has limited performance in detecting prostate cancer. The transcription factor GATA2 is expressed in aggressive prostate cancer. We analyzed the predictive value of urine extracellular vesicle GATA2 mRNA alone and in combination with a multigene panel to improve detection of prostate cancer and high risk disease. MATERIALS AND METHODS: GATA2 mRNA was analyzed in matched extracellular vesicles isolated from urines before and after prostatectomy (16) and paired urine and tissue prostatectomy samples (19). Extracellular vesicle GATA2 mRNA performance to distinguish prostate cancer and high grade disease was tested in training (52) and validation (165) cohorts. The predictive value of a multigene score including GATA2, PCA3 and TMPRSS2-ERG (GAPT-E) was tested in both cohorts. RESULTS: Confirming its prostate origin, urine extracellular vesicle GATA2 mRNA levels decreased significantly after prostatectomy and correlated with prostate cancer tissue GATA2 mRNA levels. In the training and validation cohort GATA2 discriminated prostate cancer (AUC 0.74 and 0.66) and high grade disease (AUC 0.78 and 0.65), respectively. Notably, the GAPT-E score improved discrimination of prostate cancer (AUC 0.84 and 0.72) and high grade cancer (AUC 0.85 and 0.71) in both cohorts when compared with each biomarker alone and PT-E (PCA3 and TMPRSS2-ERG). A GAPT-E score for high grade prostate cancer would avoid 92.1% of unnecessary prostate biopsies, compared to 61.9% when a PT-E score is used. CONCLUSIONS: Urine extracellular vesicle GATA2 mRNA analysis improves the detection of high risk prostate cancer and may reduce the number of unnecessary biopsies.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Woo J, Santasusagna S, Banks J, et al. Urine Extracellular Vesicle GATA2 mRNA Discriminates Biopsy Result in Men with Suspicion of Prostate Cancer. J Urol. 2020. PMID: 32250729. doi:10.1097/JU.0000000000001066

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。